Recursion Pharmaceuticals, Inc. (RXRX)
Recursion Pharmaceuticals, Inc. (RXRX) is a healthcare company (biotechnology) based in the United States. The share price is $2.70, down 7.06% on the day, which values the company at $1.68B. Price as of 17 Nov 2026, 20:35 UTC, from Yahoo Finance.
Key facts
- Share price
- $2.70−7.06% today
- Market value
- $1.68B
- Funk Score
- 52/100
- Against its own history
- Well below its usual priceusual price $6.35
- 200-week average
- $6.4258% below
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Recursion Pharmaceuticals, Inc. in more detail
RXRX trades at -3.3× next year's expected earnings, 24.7× sales. Measured against its own history, the price is 57% below what its usual multiples would imply ($6.35) — well below its usual price. It sits 58% below its 200-week average of $6.42.
Over the last five fiscal years Recursion Pharmaceuticals, Inc. has compounded revenue 79.7% a year. Its Funk Score is 52 out of 100 (financial strength 3.6, profitability 2.0, growth 10.0, value 5.0, each out of 10).
In its favour: Five straight years of revenue growth; More cash than debt. Worth checking: Altman Z in the distress zone; Beneish M-score flags the accounts.
2 of the superinvestors tracked here hold RXRX, including Cathie Wood (1.1% of the portfolio), Baillie Gifford team (0.1% of the portfolio).
Superinvestors holding RXRX
2 of the investors tracked here report a position in their latest 13F filing.
- Cathie Wood ARK Invest1.06% of portfolio · $184.8M · added · Q3 2026
- Baillie Gifford team Baillie Gifford & Co0.07% of portfolio · $75.1M · trimmed · Q3 2026
Recursion Pharmaceuticals, Inc. (RXRX): questions and answers
What is Recursion Pharmaceuticals, Inc.'s market cap?
Recursion Pharmaceuticals, Inc. is valued at $1.68B at a share price of $2.70.
Is RXRX overvalued or undervalued?
Against its own history, RXRX is well below its usual price: the price is 57% below the $6.35 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is RXRX above its 200-week moving average?
No. RXRX is 58.0% below its 200-week average of $6.42. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Recursion Pharmaceuticals, Inc. growing?
Over the last five fiscal years Recursion Pharmaceuticals, Inc.'s revenue grew 79.7% a year.
Does RXRX pay a dividend?
Recursion Pharmaceuticals, Inc. does not currently pay a regular dividend.
Which famous investors own RXRX?
In their latest quarterly filings, Cathie Wood (1.1% of the portfolio), Baillie Gifford team (0.1% of the portfolio) hold RXRX. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Recursion Pharmaceuticals, Inc. (RXRX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/RXRX
Underlying data: Yahoo Finance; company filings with the SEC.